RecruitingPhase 1NCT06712810
Q702 for the Treatment of Patients With Hematologic Malignancies
Studying Histiocytic sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayo Clinic
- Principal Investigator
- Jithma P. Abeykoon, MDMayo Clinic in Rochester
- Intervention
- Axl/Mer/CSF1R Inhibitor Q702(drug)
- Enrollment
- 46 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2030
Study locations (2)
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
- Mayo Clinic in Rochester, Rochester, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06712810 on ClinicalTrials.gov